Comparison of Remimazolam and Propofol for Drug‐Induced Sleep Endoscopy: A Randomized Clinical Trial

Authors:

Abstract
Objective: To compare the efficacy and safety of remimazolam with those of propofol for drug‐induced sleep endoscopy (DISE) in patients with obstructive sleep apnea‐hypopnea syndrome (OSAHS).Study Design: A prospective, single‐center, randomized clinical trial.Setting: Xiangya Hospital of Central South University.Methods: Patients with OSAHS receiving DISE were randomly assigned to either the remimazolam or propofol group. The primary outcome was the incidence of hypoxemia (pulse oxygen saturation [SpO2] < 90%) during DISE. The secondary outcomes were the incidence of severe hypoxemia (SpO2 < 80%), the minimal value of SpO2, sedation success rate (completion of DISE according to the medication regimen), and incidence of events of interest (including injection pain, bradycardia, and decreased respiratory rate).Results: Sixty‐four patients were included in this study. The incidence of hypoxemia was significantly lower in the remimazolam than in the propofol group (25.00% vs 62.50%, respectively; relative risk, 0.40; 95% confidence interval [CI], 0.20‐0.74; p < .01). There was no significant difference in the sedation success rate between the remimazolam and propofol groups (96.88% vs 81.25%, respectively; relative risk, 1.19; 95% CI, 1.01‐1.50; p = .10). The incidence of at least 1 event of interest was lower in the remimazolam than in the propofol group (43.75% vs 96.88%, respectively; relative risk, 0.45; 95% CI, 0.29‐0.63; p < .01).Conclusion: Remimazolam can present satisfactory sedative efficacy in DISE, with a lower incidence of hypoxemia and a higher safety profile than propofol.

This publication has 35 references indexed in Scilit: